Dolodol

Quick links to important sections

Dolodol

Treatment option: Pain, Chronic Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolodol

Property Description
Active ingredient Tramadol Hydrochloride
Form Oral tablets, capsules, solution for injection
Pharmacological class Centrally acting analgesic, Opioid analgesic
General purpose Relief from pain
Origin Synthetic compound

What Type of Medicine is Dolodol?

Dolodol is a prescription-only medicine whose active component is Tramadol Hydrochloride, a synthetic compound that is clinically recognized and classified as a centrally acting analgesic. It belongs to the broader class of opioid analgesics. Its primary purpose is to provide relief from pain by influencing the way signals of discomfort are processed within the central nervous system. Tramadol is chemically distinct from certain traditional opioids by being a racemic mixture, a characteristic derived from its synthesis process.


Composition and Available Forms of Dolodol

The medicine's essential component is the chemical entity Tramadol Hydrochloride, formulated with pharmaceutical excipients for solid dosage forms or an aqueous vehicle for injection. Dolodol is commercially available in several key dosage forms, including oral tablets, oral capsules, and a solution for injection. The oral preparations often include both immediate-release (IR) and extended-release (ER) formats, allowing for flexible delivery of the active component to suit varying patient needs, such as managing sustained discomfort over several hours.


How Does Tramadol Achieve Pain Relief?

Tramadol provides relief from pain by employing a dual mechanism of action, a key factor in its therapeutic profile. The first mechanism involves the drug binding to the μ-opioid receptor sites, which are principal regulators in the body’s pain-control system. The second, complementary mechanism involves Tramadol acting as an inhibitor of the reuptake of the natural neurotransmitters serotonin and norepinephrine. This combined approach effectively enhances the body’s own inhibitory pathways, ensuring the disruption of pain signal perception and transmission within the central nervous system.

Regulatory References

  1. Tramadol: MedlinePlus Drug Information
  2. Tramadol Pharmacology and Dual Mechanism of Action

What side effects are possible with Dolodol?

Possible Side Effects and Safety Information

The safety profile for Dolodol (Tramadol Hydrochloride) is defined by official classifications in government regulatory documents, grouping potential effects by frequency and System Organ Class (SOC).

Official Classification of Adverse Reactions

The most frequently reported adverse reactions generally affect the Nervous System and the Gastrointestinal System.

  • Very Common Reactions (affecting more than 1 in 10 people) include Nausea and Dizziness.
  • Common Reactions (affecting 1 to 10 out of 100 people) include Constipation, Vomiting, Headache, Somnolence (drowsiness), and Dry Mouth.

Serious Safety Considerations

The medicine carries high-level regulatory warnings regarding several serious safety concerns. As an opioid analgesic, a risk of Addiction, Abuse, and Misuse exists, along with the potential for developing Tolerance and Physical Dependence with prolonged use. Serious, life-threatening, or fatal Respiratory Depression has been reported, particularly when initiating treatment or increasing the dose.

The risk of Seizures (convulsions) is documented, occurring both within the recommended dose range and with higher doses. There is also a risk of Serotonin Syndrome when used alone or with other serotonergic medicines.

Population-Specific Safety Notes

Official labeling includes specific constraints for certain groups. Tramadol is contraindicated in children younger than 12 years of age. Use requires caution in older adults and in patients with severe hepatic or renal impairment. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome in the newborn.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Dolodol (Tramadol Hydrochloride) is officially documented to present with severe clinical manifestations that require immediate medical attention. These presentations include profound central nervous system (CNS) depression, respiratory depression, seizures, coma, and severe hypotension. Miosis and metabolic acidosis are also documented signs. The physiological systems primarily affected are the respiratory, CNS, and cardiovascular systems.

The most serious outcome is life-threatening respiratory depression, which is the primary cause of fatality in overdose cases. Another documented severe risk is the development of Serotonin Syndrome. Due to these risks, regulatory bodies mandate that immediate medical attention must be sought for suspected overdose or any symptoms of profound sedation, coma, or respiratory distress. Accidental ingestion of even one tablet by a child constitutes a medical emergency.

Management procedures are defined by the regulatory profile, which identifies toxicity as having both opioid and non-opioid components. Naloxone is the available antagonist to reverse opioid-induced respiratory depression and coma. However, supportive and symptomatic treatment, including airway management and providing ventilatory support, is required for non-opioid effects like seizures. Close monitoring is required following any intervention. Specific considerations note that pediatric patients face a life-threatening risk from accidental ingestion, and elderly or debilitated patients have an increased risk of respiratory depression.

Therapeutic Uses of Dolodol

What Dolodol Treats: Main Uses and Benefits

The primary role of Dolodol (Tramadol Hydrochloride) is to offer analgesic support for managing symptoms related to physical discomfort in clinical settings. This medication is applied when appropriate in situations where the level of physical distress warrants an approach targeting symptoms related to physical discomfort, providing support that helps ease the overall symptom burden.

Relief for Moderate to Severe Pain

This medication is applied in addressing symptomatic discomfort where symptoms related to physical discomfort are commonly classified as moderate to severe. It is considered relevant for conditions marked by pronounced or heightened symptoms that significantly interfere with a patient's daily routine or rest. It supports the easing of distressing manifestations and assists patients in coping more steadily with difficult, intense episodes.

Support in Acute and Chronic Pain Scenarios

Dolodol plays a role in managing symptoms related to physical discomfort across various clinical contexts, including acute episodes after surgery (postoperative care) or following a serious injury (trauma). It is commonly used for conditions characterized by persistent chronic pain, such as long-term musculoskeletal discomfort, where its primary benefit contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.


“The goal is generally to reduce the symptomatic manifestations that interfere with daily functioning and rest.”


Quick Fact: Relief for Moderate to Severe Pain

Dolodol is applied in addressing symptomatic discomfort where pain is typically moderate to severe, helping patients manage acute episodes and providing supportive relief when symptoms are persistent.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and restriction rules for Dolodol (Tramadol Hydrochloride), based strictly on regulatory documentation from agencies such as the FDA and EMA.

Contraindicated Populations

Dolodol is contraindicated (must not be used) in several specific groups:

  • Pediatric patients younger than 12 years of age.
  • Children and adolescents younger than 18 years of age following tonsillectomy and/or adenoidectomy.
  • Individuals with uncontrolled epilepsy, severe respiratory depression, or acute intoxication by alcohol, opioids, or hypnotics.
  • Patients currently taking or having recently taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Conditional Use and Restrictions

Use is restricted or conditional for other populations:

  • Age: Adults are generally eligible. Caution is advised for those over 75 years due to prolonged elimination.
  • Organ Function: Severe renal impairment (creatinine clearance < 30 mL/min) and severe hepatic impairment are criteria for restricted use, often resulting in non-eligibility for extended-release formulations.
  • Reproductive Status: Use is not recommended during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome, and is similarly not recommended while breastfeeding.
  • Comorbidities: Patients with a history of seizures or those at risk of substance dependence must use the medicine only if compelling circumstances exist and under close medical supervision.

What should I know about interactions with other medicines?

Concurrent use of Dolodol with other medicines or products is subject to official regulatory restrictions primarily focused on preventing severe adverse outcomes and managing changes in drug exposure.

Interaction Classification Relevant Interacting Agents/Categories
Forbidden/Contraindicated Monoamine Oxidase Inhibitors (MAOIs) or use within 14 days of MAOIs. Other products containing acetaminophen or tramadol.
High Risk/Precautionary Use Benzodiazepines, other Central Nervous System (CNS) depressants (including alcohol), and serotonergic drugs.

Simultaneous use with CNS depressants carries an official warning regarding the risk of profound sedation, respiratory depression, coma, and death. Combining with serotonergic drugs, such as certain antidepressants, is also associated with the risk of Serotonin Syndrome.

Interactions affecting Cytochrome P450 isoenzymes (CYP2D6, CYP3A4 inhibitors/inducers) may alter the concentrations of the drug and its active metabolites. Specific official warnings also apply to the co-administration with blood thinning agents like warfarin due to altered anticoagulant effects, and to the use with three or more daily alcoholic drinks due to the increased risk of liver damage.

Mechanism of Action

Central Modulation via Dual Pathways

Dolodol (Tramadol Hydrochloride) modulates central nervous system activity by engaging two distinct mechanisms. The drug and its active metabolite (M1), which exhibits significantly higher affinity for the mu-opioid receptor, act as agonists at the mu-opioid receptor (mu-OR), directly inhibiting the transmission of nociceptive signals. Simultaneously, the drug inhibits the reuptake of the neurotransmitters norepinephrine and serotonin, amplifying the body's natural descending inhibitory pathways. This complementary dual action contributes to the modulation of nociceptive signaling.


Metabolic Dependency on CYP2D6

The final magnitude of the mu-opioid mechanism is reliant on a metabolic bioactivation step. The parent drug, Tramadol, is converted to the M1 metabolite, which exhibits significantly higher affinity for the mu-opioid receptor, by the liver enzyme CYP2D6. This enzyme-mediated process means that the activity of the mu-opioid component is intrinsically linked to individual metabolic capacity, which determines the resulting magnitude and duration of the mechanism’s central activity.

Dosage and Administration Information

How Dolodol is Used: Official Administration Guidelines

Dolodol (Tramadol Hydrochloride) is administered according to specific regulatory protocols that define the route, dose, and frequency of use, ensuring adherence to official prescribing information. The medicine is available for oral intake, including both immediate-release (IR) and extended-release (ER) forms, as well as for parenteral routes, such as intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection.


Dosage and Frequency

Formulation Type Standard Regimen Maximum Daily Dose
Immediate-Release (IR) 50 mg to 100 mg every 4 to 6 hours as needed. 400 mg
Extended-Release (ER) Typically starts at 100 mg once daily. 300 mg

These standard dose ranges and intervals are established by regulatory bodies, with the ER formulation designed for scheduled, once-daily use. Oral preparations may be taken without regard to meals.


Specific Administration Requirements

Use of Dolodol is subject to mandatory procedural constraints outlined in the official label. Extended-release tablets and capsules must be swallowed whole and must not be crushed, chewed, or split to maintain the intended release profile. Furthermore, the dosing plan requires modification for certain patient groups. For adults over 75 years, the maximum daily dose of IR formulations is generally limited to 300 mg. In patients with severe renal impairment, the IR dosing interval is extended to 12 hours, with the maximum daily dose restricted to 200 mg.

Dolodol is used for both short-term acute periods and as part of a long-term plan. Upon discontinuation following chronic use, a gradual dose reduction (taper) is required by regulatory protocols instead of abrupt cessation.

Recent Clinical Evidence

Research evidence / Overview of studies for Dolodol

Evidence from Studies for Moderate to Severe Acute Pain

Research has been conducted exploring how symptoms change over time, primarily focusing on where the medicine was evaluated in conditions associated with acute or disruptive episodes, such as after a sudden injury or following a surgical procedure. A primary source of data is short-term randomized controlled trials (RCTs). In these studies, researchers monitored patient-reported outcomes describing perceived discomfort and measured patient-reported outcomes describing perceived discomfort over defined time intervals. Studies conducted during periods of increased symptom activity reported measurements related to the primary study endpoints. Findings describe patterns observed in the studies where a lower measured need for additional pain medication was reported in the medicine groups during the short observation period.

Evidence from Studies for Moderate to Severe Chronic Pain

The medicine was evaluated in research contexts involving fluctuating or unstable symptoms typical of persistent chronic pain conditions, such as knee and hip osteoarthritis or long-term back discomfort. The evidence landscape for chronic use is largely based on systematic reviews and meta-analyses of RCTs, where the majority of individual trials had follow-up durations of 12 weeks or less. Research describes changes measured during the study period; findings indicate that patient-reported outcomes describing perceived discomfort were recorded over the intermediate-term duration of the trials. However, for many types of persistent discomfort, the data show patterns related to measured changes in pain scores that have been described as limited in some systematic reviews.

Areas of Uncertainty and Research Gaps

Long-term effects are not fully established. A primary limitation is that the follow-up durations were limited in many of the core randomized controlled trials, making it difficult to draw conclusions about the effects on outcomes related to systemic or functional imbalance over the long term. Evidence quality varies across studies, and findings were mixed. Data for certain groups, such as pediatric patients and those with multiple concurrent conditions, remain insufficient, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Dolodol (FAQ)

Q: What are the most common things Dolodol is used for?

Official regulatory documents indicate that Dolodol is approved for managing moderate to moderately severe pain. The immediate-release formulations are generally used for shorter periods of treatment, while the extended-release forms are intended for the long-term, around-the-clock management of severe pain.


Q: Is Dolodol considered a strong medicine?

Official information classifies Dolodol as an opioid analgesic. It is indicated for moderate to moderately severe pain and acts within the central nervous system. This classification places it among medicines that influence how the body processes discomfort.


Q: How quickly should I expect Dolodol to start working?

The speed at which the medicine begins to work can vary among individuals. Official documents note that the drug’s activity is linked to a metabolic process involving a specific liver enzyme. Because this enzyme varies in activity from person to person, the resulting central activity and speed of onset can be inconsistent.


Q: Is it normal to feel a tingling sensation after taking Dolodol?

Official product information lists the potential effects of Dolodol. While various effects are documented, a tingling sensation (paresthesia) is not listed among the most frequent adverse reactions reported. If unexpected sensations occur, consulting a healthcare provider is generally recommended.


Q: What happens if I miss a scheduled dose of Dolodol?

Official guidance typically addresses missed doses by instructing users to follow their regular schedule, without taking extra medicine to compensate. It is important to refer to the official patient information provided with your prescription.


Q: Are there any known issues with taking Dolodol with herbal supplements?

Official guidance usually suggests caution when taking Dolodol alongside herbal remedies or supplements. These products are not always tested in the same way as prescription medicines, and therefore, their potential effects on how the body breaks down (metabolizes) Dolodol are often unknown.


Q: Can Dolodol affect blood pressure levels?

Yes, official regulatory documents note a risk of severe hypotension (very low blood pressure) when taking Dolodol. This risk includes orthostatic hypotension (a drop in pressure when standing up) and syncope (fainting), particularly in individuals whose blood pressure control is already compromised.


Q: What is the recommended approach if Dolodol doesn't seem to be working?

Official documents suggest contacting a healthcare provider for further evaluation if the medicine is not working as expected. Regulatory documents advise patients not to increase the dose on their own.


Q: Are there any specific laboratory tests that can be affected by taking Dolodol?

Yes, regulatory documents indicate that Dolodol and its breakdown products (metabolites) can be detected in various samples. The medicine may be detected in urine samples through specific laboratory testing methods.


Q: What does official guidance say about driving or operating machinery while taking Dolodol?

Official guidance warns that Dolodol may impair the mental and physical abilities necessary to perform potentially hazardous tasks. The guidance indicates that driving or operating machinery should be avoided until an individual understands how the medicine affects their cognitive function.


Q: How is Dolodol different from ibuprofen or acetaminophen?

The official classification distinguishes Dolodol as an opioid analgesic that acts in the central nervous system and is a Schedule IV controlled substance. Conversely, ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen is a non-opioid analgesic. These common pain relievers are not classified as controlled substances.


Q: Why does the packaging list so many potential side effects?

The extensive list of potential side effects is a mandatory regulatory requirement (e.g., FDA or EMA). This ensures that patients are informed of all documented adverse events, ranging from the most common to the rare, which were observed during clinical trials and post-marketing surveillance.


Q: How does a person know if they are experiencing a serious interaction with Dolodol?

Official safety warnings advise watching for signs of severe outcomes, such as extreme drowsiness, severely slowed breathing, unusual dizziness, or fainting. It is important that severe symptoms, such as signs of Serotonin Syndrome or profound low blood pressure, are promptly reported.


Q: Does research show differences in how Dolodol affects men versus women?

Some scientific literature suggests that women may exhibit greater sensitivity to certain effects of Dolodol compared to men. Research examining the medicine’s impact may reveal differences in both behavioral and biochemical responses between sexes.


Q: Are there different brand names for the same medicine as Dolodol?

Yes, the active ingredient in Dolodol, Tramadol Hydrochloride, is available under various different brand names and generic versions, as confirmed by official drug registries like DailyMed.


Q: If I have heart disease, is Dolodol an option for me?

Official documentation does not list general heart disease as an absolute contraindication. However, caution is advised for certain conditions, as the official label notes risks such as hypotension and potential drug interactions.


Q: What is the significance of the specific dose strengths available for Dolodol?

The specific dose strengths, such as 50 mg and 100 mg, are designed to allow for individualized treatment. This enables providers to start the dosage low and adjust it as needed to achieve effective pain relief while minimizing the risk of adverse effects.


Q: What is the average duration of treatment with Dolodol?

Official product information mandates that the duration of treatment should always be matched to the clinical need. Regulatory guidance requires that the medicine not be administered for longer than absolutely necessary, and any long-term use must involve frequent and regular patient monitoring.


Q: Can I take Dolodol with common cold and flu medicines?

Official guidance indicates that combining Dolodol with cold and flu medicines requires review. Many of these products contain acetaminophen, which is contraindicated (forbidden) for use with Dolodol. Additionally, many contain dextromethorphan, which increases the risk of the serious condition known as Serotonin Syndrome.


Q: Does the time of day I take Dolodol matter?

Official patient information for the extended-release (ER) form advises taking the dose at the same time each day. This practice is intended to maintain consistent levels of the active ingredient in the body. The immediate-release (IR) form is taken as needed.


Q: Does Dolodol contain any ingredients that cause allergic reactions?

Official labeling notes that serious and rarely fatal allergic reactions (anaphylactoid reactions) have occurred. These reactions are typically triggered by either the active drug or one of the non-active ingredients (excipients) in the formulation.


Q: What makes Dolodol unique compared to similar treatments?

The primary unique feature noted in regulatory documents is its dual mechanism of action. Dolodol works in two ways: it acts as an opioid agonist on central nervous system receptors and simultaneously inhibits the reuptake of norepinephrine and serotonin.


Q: What is the main difference between Dolodol and other common over-the-counter pain relievers?

Official classification distinguishes Dolodol as an opioid analgesic that acts in the central nervous system and is a Schedule IV controlled substance. Conversely, common OTC relievers are non-opioid and are not classified as controlled substances.

How should Dolodol be stored and disposed of?

The storage and disposal of Dolodol (Tramadol Hydrochloride) must adhere strictly to regulatory requirements for controlled substances to maintain product quality and safety.

Storage Requirements

  • Temperature and Container: Store the medicine at Controlled Room Temperature, typically not exceeding 30 C (86°F), and keep the product in its original container with the lid tightly closed. The medicine must be protected from moisture and excessive heat.
  • Child Protection: Due to the risk of accidental overdose, Dolodol must be secured in a locked cabinet or secure area, out of the sight and reach of children.

Disposal Instructions

  • Preferred Method: The official regulatory guidance directs that unused or expired Dolodol be promptly disposed of through an authorized drug take-back program or collection site.
  • Household Disposal: If a take-back program is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (e.g., dirt or used coffee grounds), sealed in a bag, and then discarded in the household trash. The medication must not be disposed of in wastewater (flushed down the toilet or sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolodol found in:

A-Z Index: